Find Clinical Trials

Inclusion Criteria: * Understand and voluntarily sign and date an informed consent document prior to any study related assessments/procedures are conducted. * Histologically confirmed diagnosis of glioma * No prior treatment with temozolomide TMZ * Patient will receive temozolomide TMZ therapy as part of their standard treatment. * Males and Females ≥18 years of age at the time of signing the informed consent document. Able to understand consent forms and study materials in English * Willing to use approved methods of contraception for duration of study * Karnofsy Performance Score (KPS) of at least 60 * Patients should have stopped any anti-depressant medications by standard of care at least a month before enrolling in the trial * Willing and able to adhere to the study visit schedule and other protocol requirements. Exclusion Criteria: * Prior treatment with other chemotherapy drugs for glioma * Known hypersensitivity to Mirtazapine and 5-HT3 receptor antagonists * Life expectancy of less than three months * Pregnancy or breastfeeding.

Inclusion Criteria * Core needle biopsy demonstrating DCIS (ductal carcinoma in situ) of non-palpable, image-detected breast abnormality * Signed and dated IRB-approved written informed consent * Women 18 years of age or older * Mammographic calcifications or MRI non-mass enhancement measuring 4 cm or less in greatest dimension, including multifocal disease * Estrogen receptor positive or negative, progesterone receptor positive, negative or unknown; HER2 positive, negative or unknown DCIS is allowed * Diagnostic needle biopsy within 16 weeks of randomization * Patients must have a biopsy marker placed within the tumor bed confirmed on post biopsy imaging. * Placement of Savi scout optical reflectance marker in tumor bed area as a wireless guide for surgery and for neoRT treatment planning is preferred but not required if anatomic metallic markers are sufficient for radiation planning. Placement does not have to occur before randomization. Additionally, wire localization before surgery is permissible. * Planned lumpectomy. Mastectomy will be acceptable if lumpectomy fails by virtue of involved margins or size of lesion, or patient chooses this approach after randomization * Radiation Oncologist to ascertain feasibility of PBI prior to randomization - based on their estimation that 30% or less of the breast volume will be encompassed in the radiation fields * Patients who had a prior contralateral invasive or non-invasive (DCIS) cancer are eligible * ECOG performance status 0, 1, or 2 * Concurrent foci of atypia or lobular carcinoma in situ in the ipsilateral or contralateral breast are allowed Exclusion Criteria * Invasive carcinoma on core needle biopsy, including microinvasive carcinoma * Radiographic extent of DCIS \>4.0 cm * Mass lesion on breast imaging or palpable tumor * No residual radiographic lesion after diagnostic percutaneous core needle biopsy * Prior history of ipsilateral invasive or noninvasive breast cancer * Pregnant or breastfeeding * Prior ipsilateral breast or chest irradiation * Multicentric or multifocal DCIS, if extent is \> 4cm * Synchronous contralateral invasive or noninvasive breast cancer * Pagets' disease of the breast * Active collagen vascular disease * Positive axillary lymph nodes * Not meeting the described criteria for partial breast irradiation during initial clinical evaluation. * Psychiatric or addictive disorders or other condition, that, in the opinion of the investigator, would preclude the patient from meeting the study requirements or interfere with the interpretation of study results * Endocrine therapy is not allowed from the time of study randomization to the completion of surgery unless the endocrine therapy is being continued for a contralateral cancer

Inclusion Criteria: 1. Histopathologically and immunohistochemically confirmed ER+ and HER2- BC patients 2. Stage I-IIIA BC patients with detectable tumor sizes 3. BC patients for whom BCS is not feasible due to tumor sizes or locations (two surgeons at each institution evaluate the infeasibility of BCS) 4. Patients without distant metastasis which were identified pathologically or radiologically 5. Female patients ≥ 19 years * Diagnosis of menopause is defined as no menstruation for 1-year or both ovaries removed surgically 6. ECOG 0-2 7. Patients with adequate bone marrow function * Hemoglobin 10 g/dL, ANC 1,500/mm3, Plt 100,000/mm3 8. Patients with adequate kidney function * serum Cr ≤ 1.5 mg/dL 9. Patients with adequate liver function * Bilirubin: ≤ 1.5 times of upper normal limit * AST/ALT: ≤ 1.5 times of upper normal limit * Alkaline phosphatase: ≤ 1.5 times of upper normal limit 10. Patients who decided to voluntarily participate in this trial with written informed consent Exclusion Criteria: 1. History of treatment for ipsilateral BC or breast carcinoma in situ 2. Confirmed distant metastasis of BC 3. History of cancer other than BC 4. Pregnant (positive pregnancy test within a week of enrollment) or breast-feeding patients 5. Uncontrolled severe infection 6. Psychiatric illness or epilepsy 7. Male BC patients 8. Inability to understand and willingness to sign a written informed consent 9. Mammographic extensive microcalcification 10. Multicentral, Bilateral BC 11. History of chemotherapy or endocrine therapy on contralateral BC for the past 2 years 12. ER- 13. HER2+ 14. Undetectable and unmeasurable primary tumor size

Inclusion criteria: * Cases will be women diagnosed and surgically intervened of breast cancer, stages I and II. * Controls will be women surgically intervened of breast augmentation or reduction. Exclusion criteria: 1. For cases: * Women with antecedents of cancer or advanced tumor stage (metastasis). * Women who have received antibiotic treatment 3 months prior to recruitment, or any neoadjuvant therapy. 2. For controls: * Women with oncological, gynecological or endocrine antecedents. * Women who have received antibiotic treatment 3 months prior to recruitment.

Inclusion Criteria: 1. Age ≥18 2. Triple negative or HER2+ breast cancer (ASCO/CAP guidelines 2018)\* 3. MBC, as defined as distant disease outside of the breast and local/regional lymph nodes. Physicians' clinical judgment will be used to determine the possible need for biopsy in confirming a MBC diagnosis. However, biopsy of a metastatic site is not required for pathologic confirmation of stage IV disease. 4. Diagnosis of metastatic disease within 12 weeks prior to study enrollment. 5. No symptoms of BrM or known asymptomatic BrM at study entry. 6. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen may participate. * This will generally be based on the primary cancer but in the event that a metastatic site is biopsied eligibility will be based on the ER, PR and HER2 profile of the metastasis. Exclusion Criteria: 1. Inability to participate in an MRI screening program as determined by the patient and/or physician. This may be on the basis of severe claustrophobia, performance status that limits additional testing, or a metal foreign body that would prevent MRI imaging. 2. Inability to provide informed consent. Notably participants who require translators are allowed to enroll. 3. Creatinine clearance \<30 mL/min using the Cockcroft-Gault equation. 4. Established need for brain imaging apart from the breast cancer diagnosis (e.g surveillance for an aneurysm). 5. ECOG Performance status \>2. 6. Pregnancy. 7. Grade 3+ allergy to Gadavist IV contrast (CTEP Adverse Event Reporting System).

Inclusion Criteria: * Histological evidence of breast cancer * Histological and/or radiological evidence of metastases * Metastasis within 10 years of registry initiation * Signed informed consent (if a patient has already died at the time of entry, the entry can be made without a declaration of consent) Exclusion Criteria: * Due to the non-interventional design of the registry there are no specific exclusion criteria.

Inclusion Criteria: * admitted to pediatric acute wards in the participating hospitals in Norway, Finland, Sweden. * referred for first severe wheezing episode, defined as first-time acute breathing difficulty with wheezing ever, appearing less than 7 days from onset of symptoms * one or more of the following:(a) fever, (b) hypoxia (SAT O2 \<= 92%), (c) retractions (inter-, subcostal), (d) prolonged expiration (on auscultation), (e) expiratory rhonchi (on auscultation) * evidence of rhinovirus infection by PCR-test in nasopharyngeal secretions * signed informed consent and expected cooperation of the patients for the treatment and follow-up must be obtained and documented according to ICH GCP, and national/local regulations. Exclusion Criteria: * previous episodes with wheezing, defined as a history of acute breathing difficulty with wheezing in need of treatment at a general practitioner or at hospital, or parental information about similar breathing difficulties * gestational age \<37 weeks * chronic illness other than atopy (eczema), * previous systemic or inhaled corticosteroid treatment, * participation to another trial, * varicella infection or contact during the last 2-3 weeks, * need for intensive care unit treatment during the present infection, except for respiratory support with non-invasive methods (high flow nasal cannula ventilation, CPAP or BiPAP), * any reason why, in the opinion of the investigator, the patient should not participate (e.g. not able to comply with study procedures). * COVID-19 related disease.

Inclusion Criteria: * BMI ≥ 25-30 kg/m2 * BMI ≥ 30 kg/m2 with Metabolic syndrome * BMI ≥ 35 kg/m2 for morbid obesity Exclusion Criteria: * Other kind of hepatic diseases * Under medications known to affect liver fat * Waist circumference ≥ 150 cm * Weight ≥ 250 kg * MRI contraindications

Inclusion Criteria: * Women with clinically suspicious or confirmed breast cancer masses (that have not been surgically removed) and will/have already undergo/undergone breast magnetic resonance imaging (MRI). Exclusion Criteria: * Pregnant women (there are no known risks to these procedures, but any unforeseen risks are as yet undetermined, so pregnant women will be excluded by means of a verbal confirmation at time of screening). * Women who have had breast implants in the previous 6 months. * Women who have had lumpectomy * Adults unable to consent. * Individuals who are not yet adults (infants, children, teenagers). * Pregnant women. * Prisoners. * There is no direct benefit of the study to any subject either non-English or English speaker. To facilitate the consent process, we will exclude non-English speaking subjects.

Inclusion Criteria: * Age≥18, male or female * Clinical diagnosed as type 2 diabetes mellitus * The presence of renal impairment including: microalbuminuria or overt proteinuria or renal insufficiency * The renal biopsy was performed with complete renal pathological diagnosis * Obtaining the signed informed consent from patients Exclusion Criteria: * The history of the disease was not complete * Clinical diagnosed as other secondary renal diseases * Patients with hereditary kidney disease * Autoimmune diseases * Patients with malignant tumor were expected to survive less than 6 months * Pregnancy and lactation

Inclusion Criteria: * Latino (self-identified); * Age 60+; * Subthreshold depression defined as a score ≥ 5 on the Patient Health Questionnaire (PHQ-9), OR subthreshold anxiety as defined as a score ≥ 5 on the GAD-7; * Do not meet criteria for current MDD or GAD as indicated by the Mini International Neuropsychiatric Inventory (MINI); * Voluntary informed consent for participation in the study by the participant or by the participant's legally designated guardian or conservator; * Medical clearance for participation in a health promotion intervention by a physician, physician's assistant, or nurse practitioner; * Not taking steroidal or anti-inflammatory medication (including NSAIDs) within 2 weeks of treatment randomization; * Expect to be resident in Miami for the subsequent 2 years. Exclusion Criteria: * Have met criteria for major depressive disorder or generalized anxiety disorder within the past 12 months; * Have met criteria for alcohol or other substance abuse disorders within the past 12 months; * Are currently receiving antidepressant medication or participating in other mental health treatment; * Have a lifetime history of bipolar disorder or other psychotic disorder including major depression with psychotic features; * Have a diagnosis of any neurodegenerative disorder or dementia (Parkinson's disease, Alzheimer's, vascular, frontotemporal dementia, etc.) or significant cognitive impairment as indicated by a Mini Mental Status Exam (MMSE) score \<24; * Are current tobacco smokers since smoking influences systemic inflammation; * Have contraindications to physical activity outlined in the American College of Sports Medicine standards; * Have high suicide risk, i.e., intent or plan to attempt suicide in the near future (a response of "yes" to questions 3, 4, and/or 5 on the Paykel Questionnaire; * Are unable to complete 10 m walk test; * Currently residing in a nursing or group home; * Have a terminal physical illness expected to result in the death within one year; * Any evidence of current infection; and * Have an acute or severe medical illness that precludes them from safely participating in a health promotion intervention (further defined in the protocol).

Inclusion Criteria * Sedentary (regular aerobic exercise frequency ≤2 times per week and duration ≤20 minutes per session; sedentary profession); * 30-50 years of age; * Control normotensive (systolic BP: 90-120 mmHg/diastolic BP: 60-80 mmHg) * Elevated to Stage 1 Hypertension (systolic BP: 120-129 mmHg/diastolic BP: 80-89 mmHg) and/or stage 1 hypertension (systolic BP: 130-159 mmHg/diastolic BP: 90-99 mmHg). Exclusion Criteria Diagnosed with any of the following: * Uncontrolled hypertension, stroke, history of heart attack, heart disease; * Metabolic disease (diabetes mellitus); * Inflammatory diseases (inflammatory bowel disease(s), rheumatoid arthritis, and systemic lupus erythematosus); * Kidney stones or gallbladder problems; * Kidney disease; * Liver disease; * Lung disease; * Cancer within the previous 6 months; (11) pregnant females; * Peripheral vascular disease; * Taking hypertension medications or those known to affect inflammation or metabolic function (anti-inflammatories, statins, thyroid medication) in the past 1 month; * Currently smoking; * Other conditions that would exclude vigorous exercise (\>2mV ST-segment depression or CVD signs and symptoms during the screening graded exercise test).

Inclusion Criteria: * Male, age 18-65 years * Willing and able to provide informed consent and follow all study procedures, including providing sperm specimens 3 months apart. * Type 1 or type 2 diabetes diagnosis confirmed by an endocrinologist (for participants in the diabetes groups) * HbA1c \> 7% (for participants in the diabetes groups) * Overweight (BMI \> 25 kg/m2) (for all groups, to ensure groups are similar) Exclusion Criteria: * Chronic kidney disease stage 4 or 5 (including end-stage renal disease); * Hepatic disease, including serum alanine transaminase (ALT) or aspartate aminotransferase (AST) greater than or equal to 3 times the upper limit of normal; hepatic synthetic insufficiency as defined as serum albumin \< 3.0 g/dL; or serum bilirubin \> 2.0; * Severe diabetic retinopathy; * Congestive heart failure, New York Heart Association (NYHA) class II, III or IV; * History of myocardial infarction, unstable angina or revascularization within the past 6 months; * Active genitourinary infection; * Testicular volume \<12 mL (assessed using Prader orchidometer); * Hypogonadism, defined as total testosterone \<250 ng/dl; * Hyperprolactinemia, defined as prolactin \>18 ng/ml; * Hyperestrogenism, defined as estradiol \>42 pg/ml; * Cryptorchidism; * Cigarette smoking; * Active alcohol abuse or substance abuse; * Cancer (except localized non-melanoma skin cancers) or use of chemotherapy agents within 5 years; * Use of nitrates or guanylate cyclase stimulators; * Use of steroid hormones (including testosterone), other than inhalers for reactive airway disease

Inclusion Criteria: The patient must be in a major depressive disorder (MDD) episode for ≥ two years or have had at least four episodes of MDD, including the current episode. The patient's depressive illness meets a minimum criterion of four prior failed treatments of adequate dose and duration as measured by a tool designed for this purpose. The patient is experiencing a major depressive episode (MDE) as measured by a guideline recommended depression scale assessment tool on two visits, within a 45-day span prior to implantation of the VNS device. Patients must maintain a stable medication regimen for at least four weeks before device implantation. Exclusion Criteria: Current or lifetime history of psychotic features in any MDE; Current or lifetime history of schizophrenia or schizoaffective disorder; Current or lifetime history of any other psychotic disorder; Current or lifetime history of rapid cycling bipolar disorder; Current secondary diagnosis of delirium, dementia, amnesia, or other cognitive disorder; Current suicidal intent; or Treatment with another investigational device or investigational drugs.

Eligibility Criteria * 21 to 85 Years of age * Diagnosis of Stage I, II or III cancer * Histologically-proven malignancy * Receiving or within one year of having received cancer treatment with radiation and/or chemotherapy * Montgomery and Åsberg Depression Rating Scale (MADRS) ≥ 20 (moderate to severe depressive symptoms) * Duration of depressive symptoms ≥ 2 weeks by patient report. * No active/acute suicidality requiring immediate care or psychiatric hospitalization * Sufficient English language proficiency to complete all assessments without assistance * Able to swallow pills * No severe anemia, defined as hemoglobin \< 10 g/dL * No history of multiple adverse drug reactions or allergy to study drugs * Not pregnant * No history of head trauma * No history of epilepsy * No other concurrent antidepressant medications Exclusion Criteria * Have a current or previous diagnosis of or history consistent with obsessive-compulsive disorder, posttraumatic stress disorder, bipolar I or II, manic or hypomanic episodes, schizophrenia, major Axis II disorders which might compromise the study, or major depression with psychotic symptoms, as assessed using the MINI International Neuropsychiatric Interview (MINI Plus). * Have a documented history of an intellectual disability. * Use of any antidepressant medication in the last 2 weeks before visit 1 (4 weeks for fluoxetine). * Currently being treated with tamoxifen. * Subjects who were non-responsive to two or more courses of antidepressant medications given at an adequate dosage\* for symptom treatment within four weeks, or by the judgment of the investigator considered to have treatment resistant depression (TRD), or a history of electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS) or psychosurgery within the last year. * Have a history of any seizure disorder. * Any clinically significant abnormal vital sign, ECG, or laboratory values as determined by the investigator which might interfere with the study. * Have a high suicidal risk as assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS). High suicidal risk is indicated by: 1. A positive response to question 4 or 5, indicating endorsement of suicidal ideation with at least some intent to act in the past month; and/or 2. A positive response to part two of question 6, indicating the presence of any suicidal behavior in the past 3 months. * Have a history of substance dependence/abuse\*\* within the past 6 months or a positive drug screen result during the screening period. * Have a history of severe allergies to more than 1 class of medication or multiple adverse drug reactions. * \* An adequate dosage of the antidepressant medication is defined as the average of the usual dose (mg/day) recommended in American Psychiatric Association (APA) Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition. E.g. the usual dose of Citalopram is 20-60 mg/day, the adequate dosage is 40 mg/day. * \*\* Tobacco is excluded here, and alcohol abuse is defined as average pure alcohol intake is more than 112 g (for male) or 56 g (for female) per week and/or with Alcohol withdrawal syndrome. Pure alcohol intake =% (Concentration or alcohol content) x c.c. (volume)x 0.79 (density of alcohol). Result of serum ethanol test should be equal to or lower than 10.0 mg/dL to be determined as eligible for the trial. If test result is between 10.1 to 29.9 mg/dL, only one re-test is allowed per subject to meet the criterion. Subject with test result equal to or higher than 30.0 mg/dL is to be excluded.

Inclusion Criteria: * Participants must have histologically or cytologically confirmed breast cancer that is human epidermal growth factor receptor 2 negative (HER2-negative) per the most recent 2018 ASCO CAP guidelines94 * Estrogen Receptor and Progesterone immunohistochemistry (IHC) status must be known; any status is eligible, but this will define in which cohort a patient will enroll: * Additional eligibility for cohort 1: Triple negative disease- defined as IHC staining of \<10% for ER and PR per local pathology review * Additional eligibility for cohort 2: Hormone receptor-positive disease defined as IHC for ER or PR \>/= 10% per local pathology review * Men and women are eligible * Age 70 and older at the time of protocol registration * Non-metastatic, invasive breast cancer (scans are not required to document non-metastatic disease- any staging work-up is up to the treating provider's discretion) * Recommended to have either neoadjuvant chemotherapy or adjuvant chemotherapy per their treating provider. * Any surgery, nodal assessment, radiation, hormonal therapy is left up to the treating provider but should not occur concurrently with study therapy. If any additional chemotherapy is planned by a treating provider, this must occur AFTER all study-related chemotherapy is completed. * Any patient receiving pre-operative hormonal therapy and who is then recommended for adjuvant chemotherapy is eligible, though hormonal therapy should be held during study treatment administration * All study-related chemotherapy must be given prior to surgery if neoadjuvant therapy is planned or adjuvantly if postoperative chemotherapy is planned. For example, giving 6 doses pre-operatively and 6 doses postoperatively is not allowed on study. * There are no restrictions on life expectancy, ECOG Performance Status, or baseline blood values or organ function; Appropriateness of chemotherapy treatment is left up to the treating provider but providers should be ok with the full starting doses of each agent. * Participants must be willing to fill out surveys over time or designate a proxy to answer on their behalf. * Ability to understand and the willingness to sign a written informed consent document. * Patients who do not speak or read English are eligible as long as adequate interpreter services are available or the surveys are available in the preferred language (i.e. PRO surveys are available in many languages) Exclusion Criteria: * Participants who have already received chemotherapy for the current cancer. Prior diagnoses of breast cancers are allowed, provided that the treating provider feels that the current cancer represents a new primary breast cancer and not recurrent disease. * Participants who are receiving any other investigational or anti-cancer agents. Any additional radiation, hormonal therapy or chemotherapy planned should be administered once the study treatments have completed. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to cyclophosphamide, carboplatin, and paclitaxel. * Prior chemotherapy receipt is allowed in the setting of treatment of other/prior cancers, but no prior carboplatin (cohort 1), cyclophosphamide (cohort 2), or paclitaxel (both cohorts) receipt in the last 2 years is allowed (given toxicity and possible efficacy concerns

Inclusion Criteria: * Healthy Volunteers age 20 to 80, recruited from Sheffield Teaching Hospitals staff members * Patients age 20 to 80 with suspected or known heart disease (group 1 to 5) * Capable of giving written informed consent Exclusion Criteria: * Inability to perform the study protocol secondary to severe heart failure requiring IV therapy * Patients recruited in the suspected CAD and acute myocardial infarction arms of the study and in need for detection of ischaemia should not have any past medical history of MI, ACS or cardiomyopathy * Patients with significant valvular heart disease will be excluded from any patient group * Patient with in atrial fibrillation will be excluded * Contraindication to MRI (as per standard MRI screening questionnaire issued to patients prior to clinical MRI procedures)

Inclusion Criteria: 1. Men and women aged 40-70 years; 2. Newly diagnosed type 2 diabetes * Duration of type 2 diabetes ≤ 2 years; * Antidiabetic treatment maintained for at least 6 weeks before recruitment; 3. 7.0%≤ HbA1c \< 9.0%; 4. 25 Kg/m2 ≤ Body mass index (BMI) \<40 Kg/m2; Exclusion Criteria: 1. History consistent with type 1 diabetes; 2. Insulin treatment; 3. Severe cardiovascular disease: * current angina * myocardial infarction within last six months * heart failure * symptomatic periphery vascular disease 4. Uncontrolled hypertension: systolic blood pressure \> 180 mmHg or diastolic blood pressure \> 100 mmHg; 5. Myocardial ischemia indicated by resting ECG; 6. Foot ulcers, peripheral neuropathy or skeletal disorders; 7. Taking high intensity exercise more than 75 minutes or moderate intensity exercise more than 150 minutes per week during the screening phase 8. Average weekly alcohol intake \>140 grams for men and \>70 grams for women; 9. ALT or AST levels more than twice the upper limit of the normal range or active liver diseases; 10. eGFR \<60 ml/min/1.73 m2, or serum creatinine \>1.5 mg/dl for men or 1.3mg/dl for women; or Proteinuria 11. Malignant tumor in active-stage, or in remission stage but less than 5 years from the most recent treatment 12. Hemoglobin concentration \<130 g/l for men or \<120 g/l for women; 13. Past or present confirmed psychiatric illness or drug dependence; 14. History of food allergies; 15. Surgical history of digestive system; 16. Currently taking medications known to affect weight (e.g. anti thyroid drugs, glucocorticoids); 17. Known to have weight-affecting diseases (e.g. malabsorption, functional bowel disease, uncontrolled low sodium/hyperthyroidism, eating disorders); 18. Known to have metabolism-affecting diseases; 19. Known to have infectious diseases within last month; 20. Possible consumption of food or drugs affecting glucose homeostasis or gut microbiota within the last three months; 21. Other acute diseases supported by clinical evidence which may contradict to the interventions; 22. Pregnancy, currently trying to become pregnant, or of child-bearing potential and not using birth control; 23. Currently participating in another intervention study; 24. Failure to obtain informed consent from participant; 25. Any factors judged by the clinic team to be likely to limit adherence to interventions; 26. Any other medical condition judged by the clinic team not eligible for the trial.

Inclusion Criteria: 1. Women with invasive (clinical stage I, II and III) breast cancer, for whom neoadjuvant systemic therapy with chemotherapy is recommended prior to surgery. 2. ECOG Performance status of 0 or 1. 3. Hematology and Biochemistry assessments (CBC and differential, PTT, PT/INR, AST, Alk Phos, Bilirubin, and Creatinine) within normal range unless determined not clinically significant by the qualified investigator. 4. Ability to take oral medications. 5. Adequate tissue specimen for diagnosis, biomarkers, and endpoint Ki67 assays. Exclusion Criteria: 1. Patients undergoing surgery prior to chemotherapy. 2. Current or previous (within 2 months) daily use (\>1 day/week) use of omega-3, fish oil, or other supplements or functional foods containing docosahexaenoic acid (at daily doses \> 200 mg). 3. Known allergy to soy or corn. 4. Continued intake of supplements containing Vitamin C, Vitamin E or β-carotene exceeding the DRI, or other anti-oxidant supplements. 5. Symptomatic but untreated cholelithiasis. 6. History of deep venous thrombosis, active thrombophlebitis, pulmonary embolism, stroke, acute myocardial infarction, congestive cardiac failure, untreated hypertension, known inherited hypercoagulable disorder. 7. Diagnosis of any other malignancy within the previous year except for adequately treated basal cell or squamous cell skin cancer. 8. Medically documented history of a psychiatric disorder that would preclude consent 9. Partial or complete loss of vision or diplopia, from ophthalmic vascular disease. 10. Hypersensitivity to DHA or to any ingredient in the formulation or component of the container.

Inclusion Criteria: Cohort 1: Capacity and willingness to participant in TMS, and fMRI as well as satisfying criteria for diagnosis. * Between 18 and 89 years of age. * Ability to obtain a Motor Threshold (MT) with single pulse TMS * Ability to safely and comfortably undergo an MRI and TMS * Able to read, verbalize, understand and voluntarily sign the Informed Consent Form prior to participating in any study-specific procedures or assessments * Depression (PHQ-9 \>= 10 and functional impairment present indicated with "difficulty" question OR sufficiently depressed to be enrolled in rTMS therapy) * Confirmed diagnosis of Major Depressive Disorder (MDD) * Can maintain all existing treatments (e.g. psychopharmacology, psychotherapy, etc.,) throughout course of the three sessions (psychological / functional assessments, MRI, and TMS), with modifications only as needed for clinical management * Is a Veteran Cohort 2: * Between 18 and 89 years of age * Ability to safely and comfortably undergo an MRI and tES * Ability to read, verbalize, understand, and voluntarily sign the Informed Consent Form prior to participating in any study-specific procedures or assessments * Depression (PHQ-9 \>= 10) and endorse that the COVID-19 pandemic has worsened their depression OR have a score on the COVID Stress Scale (CSS) on any item of 3 or greater indicating stressor is "very" or "often" a problem will allow the Veteran to enter the study Exclusion Criteria: * Participants who can not safely and comfortably undergo MRI OR TMS (or TES for Cohort 2) * If their language is not primarily English they may be excluded depending on how dependent the imaging and cognitive tasks are on language * Additionally, participants may be excluded if they do not fully understand the consenting process and cannot communicate sufficiently in English to participate in the therapy (d/t language barrier, etc.) * An example of safety screen details for an MRI is detailed in the Stanford University MRI screening form * MRI exclusions include having any non-removable device or implant that makes scanning unsafe, claustrophobia, and size (e.g. weight, girth) beyond the constraints of the MRI and scanner bed * For TMS the investigators will follow safety guidelines set by Rossi et. al.,2009 * Specifically, the investigators will not include subjects whose Motor Threshold (MT) is greater than 84% of maximum device output because mathematically they would not be able to be safely stimulated using the standard 120% of MT (i.e. the device cannot stimulate more than 100% of its potential output) * The investigators will report these high MT data in our secondary analyses. Additional TMS exclusions include any history or condition that puts patients at risk for a seizure * Pregnant or planning to become pregnant within the next 3 months * Lifetime history of moderate or severe traumatic brain injury, current unstable medical conditions, current (or past if appropriate) significant neurological disorder, or lifetime history of: * seizure disorder * primary or secondary CNS tumors * stroke * cerebral aneurysm * Significant cognitive impairment (Montreal Cognitive Assessment \[MoCA\] \< 16) * Comorbidities (e.g. PTSD) determined not to be the primary diagnosis * Have a lifetime diagnosis of schizophrenia, schizoaffective disorder, schizophreniform, delusional disorder, or current psychotic symptoms * Have a diagnosis of obsessive-compulsive disorder assessed by a study investigator to be causing greater impairment than MDD * Have active suicidal intent or plan in which case Dr. Rosen will determine whether the patient needs to be referred for hospitalization * Presence of any other condition or circumstance that, in opinion of the investigator team, has the potential to prevent study completion and/or to have a confounding effect on outcome assessments Exclusion Criteria for Cohort 2: * Participants who cannot safely and comfortably undergo MRI or TES * Pregnant or lactating female or planning to become pregnant within the next 3 months * Lifetime history of moderate or severe traumatic brain injury or tumor * Significant cognitive impairment (Montreal Cognitive Assessment \[MoCA\] \< 16 OR equivalent score on \[MoCA-BLIND\] and judgement of a clinician that the test is validly reflecting a significant disabling cognitive impairment * Have a lifetime diagnosis of: * schizophrenia * schizoaffective disorder * schizophreniform * delusional disorder * or current psychotic symptoms * Have a diagnosis of obsessive-compulsive disorder or unstable substance use disorder * Presence of actively infections/contagious disease such as the flu or SARS-CoV-2